Skip to main content

Advertisement

Table 3 Tumor response assessment and correlation to  KRAS  mutational status

From: Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

All patients All WT Codon 12 mutation Codon 13 mutation p-value
No. of patients% 201 128 58 15  
100 63.6 28.9 7.5
ORR% 55 63 49 23 0.008
95% CI (49–61) (54–71) (37–62) (8–51) (Chi-Square)
DCR% 85 88 81 77 0.29
95% CI (80–90) (80–92) (68–89) (49–93) (Chi-Square)
  1. All patients. Percentages based on non-missing data, p-values for WT vs Codon 12 mutations vs codon 13 mutations; WT wild type; ORR overall response rate, DCR disease control rate.